Myocardial Infarction
Early menopause tied to higher risk for incident heart failure
Women with menopause onset before age 45 years were more likely to develop incident heart failure regardless of serum adipokine levels, according to study findings published in Menopause.
‘Very small amounts’ of intense physical activity may cut heart disease risk for women
Among nonexercising women, those who initiated a few minutes of vigorous lifestyle physical activity daily had substantially lower risk for any major adverse cardiovascular event, including myocardial infarction and heart failure, data show.
Fear of recurrence consistent source of stress for heart attack survivors
CHICAGO — Survivors of an acute MI reported fear of a recurrence up to 8 months later, along with high levels of perceived stress that were distinct from depression and anxiety symptoms, researchers reported.
Breast calcification on mammogram ‘especially predictive’ of CVD risk in younger women
Breast arterial calcification seen on routine mammograms, especially among younger women, is associated with increased risk for death and adverse cardiovascular outcomes, including heart failure, myocardial infarction and stroke, data show.
‘Sparking hope,’ celebrating a century of heart health advances at AHA 2024
CHICAGO — When the American Heart Association was founded by six clinicians in June 1924, there was no treatment — and little hope — for people living with heart disease.
Adolescent risk factors can predict risk for future cardiovascular events
Childhood BMI, blood pressure and smoking status performed as well as lipid levels in predicting the risk for cardiovascular events in adulthood, according to study findings published in Pediatrics.
GLP-1, SGLT2 prescriptions for type 1 diabetes rising despite no regulatory approval
Prescriptions for GLP-1 receptor agonists and SGLT2 inhibitors for patients with type 1 diabetes rose between 2010 and 2023 despite not being approved for that population, according to a research letter published in JAMA.
Oral semaglutide prevents CV events in people with diabetes and heart disease, CKD
Oral semaglutide demonstrated an approximately 14% reduction in major adverse CV events compared with standard care along in patients with diabetes, CVD and/or kidney disease, according to the top-line results of the phase 3 SOUL trial.
Medication hesitancy when addressing patients’ obesity-related atherosclerotic risk
BOSTON — In a survey, cardiology physicians expressed hesitancy to prescribe currently available obesity medications, preferring exercise and dietary interventions, but with little personalized tailoring for patients, researchers reported.
Zyno Medical recalls select IV infusion pumps due to risk for air bubbles
Zyno Medical is recalling select Z800 infusion pumps due to a defect in the air-in-line software algorithm that may allow a 1 mL air bubble to be passed on to a patient, according to the FDA.